Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preseasonal allergoid immunotherapy with grass plus rye pollen extract for seasonal allergic rhinoconjunctivitis
2007-005452-16Phase 4Terminated
- Sponsor
- Merck KGaA
- Start
- Nov 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hypoallergenic 6 grass and rye pollen allergoid extract in allergic rhinitis (AR), allergic conjunctivitis (AC) and allergic asthma (2 arms), sponsored by Merck KGaA. Primary endpoint: Improvement in conjunctival provocation test threshold. Started Nov 2007; status: terminated.
02
Drugs
hypoallergenic 6 grass and rye pollen allergoid extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)allergic asthma
Beyond the preview
Go deeper on 2007-005452-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005452-16.